# NovoCure Ltd (NVCR)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/novocure-ltd/ JSON: https://steadybase.io/company/novocure-ltd.json Checked Nov 10, 2026. Latest filing read: Oct 29, 2026.

## Company

- Legal name: NovoCure Ltd
- Ticker: NVCR (Nasdaq)
- SEC CIK: 0001645113
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: St. Helier
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: novocure.com
- LinkedIn: https://www.linkedin.com/company/novocure-inc
- Next earnings date: Dec 18, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $655.4M for the fiscal year ended Dec 31, 2025 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.html
- Operating income: -$153.8M for the fiscal year ended Dec 31, 2025 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.html
- Net income: -$136.2M for the fiscal year ended Dec 31, 2025 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.html
- SG&A: $417.7M for the fiscal year ended Dec 31, 2025 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.html
- Employees: 1,605 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm
- Shares outstanding: 116,915,959 as of Oct 23, 2026 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.html
- Auditor: Kost Forer Gabbay & Kasierer, Israel, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm

## Business

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $655.4M | -$153.8M | -$136.2M | $417.7M |
| Dec 31, 2024 | $605.2M | -$170.5M | -$168.6M | $428.9M |
| Dec 31, 2023 | $509.3M | -$232.9M | -$207.0M | $390.9M |
| Dec 31, 2022 | $537.8M | -$89.5M | -$92.5M | $306.4M |
| Dec 31, 2021 | $535.0M | -$44.3M | -$58.4M | $263.2M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/novocure-ltd.json

## Officers and directors

- Frank X. Leonard, Chief Executive Officer. Source: Form 4 filed Jul 1, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000182287926000006/0001822879-26-000006-index.htm
- Ashley Cordova, Former Chief Executive Officer. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000182201426000003/0001822014-26-000003-index.htm
- Christoph Brackmann, Chief Financial Officer. LinkedIn: https://linkedin.com/in/christophbrackmann. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000204863426000001/0002048634-26-000001-index.htm
- Mukund Paravasthu, Chief Operating Officer. LinkedIn: https://linkedin.com/in/mukund-paravasthu-6719441. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000203907826000005/0002039078-26-000005-index.htm
- Frank Leonard, CEO, Novocure. Source: 8-K filed Oct 29, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000081/nvcr-20260930xpr.htm
- Arye Barak Ben, General Counsel. Source: Form 4 filed Jul 1, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000191716526000006/0001917165-26-000006-index.htm
- Michal Nath Puri, Chief Human Resources Officer. Source: Form 4 filed Jul 1, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000199703226000006/0001997032-26-000006-index.htm
- Nicolas Leupin, Former Chief Medical Officer. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000200776626000003/0002007766-26-000003-index.htm
- Barak Ben-Arye, General Counsel. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm
- Michael Puri, Chief Human Resources Officer. LinkedIn: https://linkedin.com/in/michaelpuri. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm
- William F. Doyle, Executive Chairman. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000119445926000001/0001194459-26-000001-index.htm
- Allyson Ocean, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Asaf Danziger, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- David Hung, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Jeryl Hilleman, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Kinyip Gabriel Leung, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Kristin Stafford, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Martin Madden, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- William Doyle, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- William Vernon, director. Source: 8-K filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Uri Weinberg, Chf Medical and Innovation Ofr. LinkedIn: https://linkedin.com/in/uri-weinberg-5293b88. Source: Form 4 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000181103026000003/0001811030-26-000003-index.htm
- Nicholas Leupin, Named in proxy. Source: DEF 14A filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1645113/000164511326000033/nvcr-20260420.htm

## Recent 8-K events

- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000081/nvcr-20261029.htm
- Oct 1, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000071/nvcr-20261001.htm
- Sep 9, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000068/nvcr-20260902.htm
- Sep 1, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000065/nvcr-20260901.htm
- Jul 23, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/nvcr-20260723.htm
- Jun 30, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/nvcr-20260630.htm
- Jun 18, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000053/nvcr-20260618.htm
- Jun 5, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000050/nvcr-20260603.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/nvcr-20260430.htm
- Apr 9, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000026/nvcr-20260408.htm

## Insider trades (Form 4)

- Nov 2, 2026: Michal Nath Puri (Chief Human Resources Officer) sold 660 shares, about $8,738. Source: https://www.sec.gov/Archives/edgar/data/1645113/000199703226000009/0001997032-26-000009-index.htm
- Jun 4, 2026: Frank X. Leonard (Chief Executive Officer) sold 34,273 shares, about $614,515. Source: https://www.sec.gov/Archives/edgar/data/1645113/000182287926000004/0001822879-26-000004-index.htm
- Jun 2, 2026: Kristin Stafford (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000197043826000001/0001970438-26-000001-index.htm
- Jun 2, 2026: Allyson J. Ocean (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000196732626000001/0001967326-26-000001-index.htm
- Jun 2, 2026: Timothy J. Scannell (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000145153326000001/0001451533-26-000001-index.htm
- Jun 2, 2026: W. Anthony Vernon (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000136909126000004/0001369091-26-000004-index.htm
- Jun 2, 2026: David Hung (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000131088026000005/0001310880-26-000005-index.htm
- Jun 2, 2026: Gabriel Leung (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000123618326000001/0001236183-26-000001-index.htm
- Jun 2, 2026: Jeryl L. Hilleman (Director) sold 2,945 shares, about $46,443. Source: https://www.sec.gov/Archives/edgar/data/1645113/000121662826000001/0001216628-26-000001-index.htm
- Mar 5, 2026: Mukund Paravasthu (Chief Operating Officer) sold 48,623 shares, about $667,065. Source: https://www.sec.gov/Archives/edgar/data/1645113/000203907826000005/0002039078-26-000005-index.htm
- Mar 4, 2026: Christoph Brackmann (Chief Financial Officer) sold 6,412 shares, about $85,344. Source: https://www.sec.gov/Archives/edgar/data/1645113/000204863426000001/0002048634-26-000001-index.htm
- Mar 4, 2026: Nicolas Leupin (Former Chief Medical Officer) sold 1,100 shares, about $14,641. Source: https://www.sec.gov/Archives/edgar/data/1645113/000200776626000003/0002007766-26-000003-index.htm
- Mar 4, 2026: Michal Nath Puri (Chief Human Resources Officer) sold 1,100 shares, about $14,641. Source: https://www.sec.gov/Archives/edgar/data/1645113/000199703226000004/0001997032-26-000004-index.htm
- Mar 4, 2026: Frank X. Leonard (Chief Executive Officer) sold 5,607 shares, about $74,629. Source: https://www.sec.gov/Archives/edgar/data/1645113/000182287926000003/0001822879-26-000003-index.htm
- Mar 4, 2026: Uri Weinberg (Chf Medical and Innovation Ofr) sold 6,412 shares, about $85,344. Source: https://www.sec.gov/Archives/edgar/data/1645113/000181103026000003/0001811030-26-000003-index.htm

## What management said

- "Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies" Frank Leonard, CEO, Novocure (8-K filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000081/nvcr-20260930xpr.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000081/nvcr-20261029.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm
- 10-Q filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/nvcr-20260930.htm
- DEF 14A filed Apr 20, 2026: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000033/nvcr-20260420.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/